Order
Now

A key dilation component in your toolkit

RYZUMVI (phentolamine ophthalmic solution) 0.75% packshot and vials

Ensure RYZUMVI® is always on hand. Streamline your ordering process today.

Step 1
Get Ready

Experience the RYZUMVI difference. Select an authorized distributor below and make it a staple in your routine orders.

Step 2
Get Set

Store RYZUMVI refrigerated at 2°C to 8°C (36°F to 46°F). Do not exceed the printed expiration date.1
Protect from freezing.

Step 3
Remember
RYZUMVI

When ready, remember to place a foil pouch in your exam areas to offer patients a redefined post-dilation experience with RYZUMVI.1
After opening the foil pouch, the product may be stored at 25°C (68°F to 77°F) and should be used within 14 days, not to exceed the expiration date printed on the vial.1
The single-patient-use vial once opened should be discarded immediately after use.1

Never miss an opportunity to offer the right patients RYZUMVI

Not an actual patient

With RYZUMVI—dilation may not need to disrupt your patient's entire day.1-3

DOSING &
ADMINISTRATION

INDICATIONS AND USAGE

RYZUMVI® (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

See full ISI

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).

Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.

Adverse Reactions

The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).

Please see Full Prescribing Information

References: 1. RYZUMVI (phentolamine ophthalmic solution). Prescribing Information. Ocuphire. 2. Goel S, Maharajan P, Chua C, Dong B, Butcher M, Bagga P. Driving ability after pupillary dilatation. Eye (Lond). 2003;17(6):735-738. 3. Siderov J, Bartlett JR, Madigan CJ. Pupillary dilation: the patient's perspective. Clin Exp Optom. 1996;79(2):62-66.